Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Create alerts with multiple filters including highs/low, comparative values, and turning points. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Silo Pharma Inc (SILO)

Silo Pharma Inc (SILO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade SILO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1033 +28.27%
on 07/14/22
0.1695 -21.83%
on 07/22/22
+0.0176 (+15.32%)
since 07/12/22
3-Month
0.0892 +48.54%
on 07/06/22
0.1695 -21.83%
on 07/22/22
-0.0126 (-8.68%)
since 05/12/22
52-Week
0.0892 +48.54%
on 07/06/22
0.2489 -46.77%
on 04/08/22
-0.0278 (-17.34%)
since 08/12/21

Most Recent Stories

More News
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam...

CYBN.NE : 1.020 (-6.42%)
SILO : 0.1325 (-4.81%)
FTRP : 0.8500 (+2.35%)
FTRP.TO : 1.11 (+0.91%)
ATAI : 4.68 (+2.18%)
CYBN : 0.8099 (+1.24%)
ENBI.CN : 0.080 (-5.88%)
ENTBF : 0.0596 (-14.86%)
CMPS : 18.35 (-0.05%)
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

/PRNewswire/ -- For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many...

ENTBF : 0.0596 (-14.86%)
FTRP.TO : 1.11 (+0.91%)
SILO : 0.1325 (-4.81%)
FTRP : 0.8500 (+2.35%)
ATAI : 4.68 (+2.18%)
CYBN : 0.8099 (+1.24%)
CMPS : 18.35 (-0.05%)
Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system ENGLEWOOD CLIFFS, N.J, July ...

SILO : 0.1325 (-4.81%)
Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients

ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announces...

SILO : 0.1325 (-4.81%)
Silo Pharma Expands License Agreement and Patent Portfolio

Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes Therapeutics Would Target Multiple Diseases Including Auto Immune...

SILO : 0.1325 (-4.81%)
Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study

Study is examining effects of Psilocybin on Inflammatory MarkersENGLEWOOD CLIFFS, N.J., May 19, 2022 (GLOBE NEWSWIRE) --  Silo Pharma, Inc . (OTCQB:...

SILO : 0.1325 (-4.81%)
Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study

SPU-21 has shown Anti-arthritic activity for therapeutic use in preclinical studies....

SILO : 0.1325 (-4.81%)
Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study

IND Enabling Study to prepare Silo Pharma Homing Peptides for Clinic...

SILO : 0.1325 (-4.81%)
IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused...

OTC.VN : 0.320 (unch)
SILO : 0.1325 (-4.81%)
Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis and inflammation Englewood Cliffs NJ, Feb. 03, 2022 (GLOBE...

SILO : 0.1325 (-4.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.1500
2nd Resistance Point 0.1445
1st Resistance Point 0.1385
Last Price 0.1325
1st Support Level 0.1270
2nd Support Level 0.1215
3rd Support Level 0.1155

See More

52-Week High 0.2489
Fibonacci 61.8% 0.1879
Fibonacci 50% 0.1690
Fibonacci 38.2% 0.1502
Last Price 0.1325
52-Week Low 0.0892

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar